THERAPY DOSSIER · th-79d3bedede8c

Paeonol (Paeonia suffruticosa extract)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04657926 ↗PHASE2completed

Combination of Apocynin and Paeonol (APPA) for the Treatment of Knee Osteoarthritis

Osteoarthritis

Enrolment: 152 · Results not recorded

NCT07429565 ↗PHASE1completed

Phase I SAD/MAD Study of APPA-1 (apocynin/paeonol) in Healthy Subjects and Osteoarthritis Patients

Osteoarthritis

Enrolment: 40 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27493631 ↗2016Reported benefit

Paeonol Protects Rat Heart by Improving Regional Blood Perfusion during No-Reflow

RatIschaemia-reperfusionCardiacWistarMalen = 8 per groupOral (intragastric)100 mg/kg and 200 mg/kgPretreatment for 7 days before ischaemia-reperfusion

Model: Left anterior descending coronary artery ligation for 4 h followed by 8 h reperfusion

Paeonol significantly reduced infarct and no-reflow areas, improved regional myocardial perfusion and cardiac function, and lowered serum LDH, creatine kinase, cardiac troponin T and C-reactive protein

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…